Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort

Imagem de Miniatura
Arquivos
art_RADANOVIC_Correlation_between_CSF_biomarkers_of_Alzheimers_disease_and_2019.PDF (524.66 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRASILEIRA PSIQUIATRIA
Autores
Citação
BRAZILIAN JOURNAL OF PSYCHIATRY, v.41, n.6, p.479-484, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: The relationship between biomarkers of amyloid-beta aggregation (A beta(1-42)) and/or neurodegeneration (Tau protein) in cerebrospinal fluid (CSF) and cognitive decline is still unclear. We aimed to ascertain whether CSF biomarkers correlate with cognitive performance in healthy and cognitively impaired subjects, starting from clinical diagnoses. Methods: We tested for correlation between CSF biomarkers and Mini-Mental State Examination (MMSE) scores in 208 subjects: 54 healthy controls, 82 with mild cognitive impairment (MCI), 46 with Alzheimer's disease (AD), and 26 with other dementias (OD). Results: MMSE correlated weakly with all CSF biomarkers in the overall sample (r = 0.242, p < 0.0006). A beta(1-42) and MMSE correlated weakly in MCI (r = 0.247, p = 0.030), and moderately in OD (r = 0.440, p = 0.027). t-Tau showed a weak inverse correlation with MMSE in controls (r = -0.284, p = 0.043) and MCI (r = -0.241, p = 0.036), and a moderate/strong correlation in OD (r = 0.665), p = 0.0003). p-Tau correlated weakly with MMSE in AD (r = -0.343, p = 0.026) and moderately in OD (r = -0.540, p = 0.0005). The A beta(1-42)/p-Tau ratio had a moderate/strong correlation with MMSE in OD (r = 0.597, p = 0.001). Conclusion: CSF biomarkers correlated best with cognitive performance in OD. t-Tau correlated weakly with cognition in controls and patients with MCI. In AD, only p-Tau levels correlated with cognitive performance. This pattern, which has been reported previously, seems to indicate that CSF biomarkers might not be reliable as indicators of disease severity.
Palavras-chave
Mild cognitive impairment, dementia, Alzheimer's disease, cerebrospinal fluid biomarkers
URI
https://observatorio.fm.usp.br/handle/OPI/34514
Referências
  1. Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008
  2. Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003
  3. [Anonymous], 1944, ARM IND TEST BATT MA
  4. Ben Bouallegue F, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0260-z
  5. Bertens D, 2015, ALZHEIMERS DEMENT, V11, P511, DOI 10.1016/j.jalz.2014.05.1754
  6. Borroni B, 2014, NEURODEGENER DIS, V13, P224, DOI 10.1159/000353280
  7. Custodio N, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00221
  8. Eckerstrom C, 2015, J ALZHEIMERS DIS, V44, P205, DOI 10.3233/JAD-141053
  9. Ferreira D, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00047
  10. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  11. FULD PA, 1980, CORTEX, V16, P255, DOI 10.1016/S0010-9452(80)80061-X
  12. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  13. Hermann P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105000
  14. Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018
  15. Jack CR, 2016, NAT REV NEUROL, V12, P117, DOI 10.1038/nrneurol.2015.251
  16. Jack CR, 2014, LANCET NEUROL, V13, P997, DOI 10.1016/S1474-4422(14)70194-2
  17. Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004
  18. Joachim LK, 2018, JPAD-J PREV ALZHEIM, V5, P202, DOI 10.14283/jpad.2018.5
  19. JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742
  20. Kandel BM, 2015, J ALZHEIMERS DIS, V46, P901, DOI 10.3233/JAD-142943
  21. Kochhann Renata, 2009, Dement. neuropsychol., V3, P88, DOI 10.1590/S1980-57642009DN30200004
  22. Koedam ELGE, 2013, ALZHEIMERS DEMENT, V9, P269, DOI 10.1016/j.jalz.2011.12.007
  23. Kortvelyessy P, 2015, J ALZHEIMERS DIS, V46, P375, DOI 10.3233/JAD-150069
  24. Koychev I, 2017, J ALZHEIMERS DIS, V60, P283, DOI 10.3233/JAD-170129
  25. Llorens F, 2016, PROG NEUROBIOL, V138, P36, DOI 10.1016/j.pneurobio.2016.03.003
  26. Mandecka M, 2016, J ALZHEIMERS DIS, V54, P157, DOI 10.3233/JAD-160176
  27. Mazzeo S, 2016, J ALZHEIMERS DIS, V54, P1495, DOI 10.3233/JAD-160360
  28. McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
  29. Nathan PJ, 2017, NEUROBIOL AGING, V53, P1, DOI 10.1016/j.neurobiolaging.2017.01.013
  30. Oeckl P, 2016, J NEUROCHEM, V138, P184, DOI 10.1111/jnc.13669
  31. Rami L, 2011, J ALZHEIMERS DIS, V23, P1, DOI 10.3233/JAD-2010-101422
  32. Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179
  33. Rolstad S, 2013, J ALZHEIMERS DIS, V34, P949, DOI 10.3233/JAD-121960
  34. Rolstad S, 2011, J ALZHEIMERS DIS, V26, P135, DOI 10.3233/JAD-2011-110038
  35. Seppala TT, 2011, J ALZHEIMERS DIS, V25, P583, DOI 10.3233/JAD-2011-101911
  36. Simonsen AH, 2017, ALZHEIMERS DEMENT, V13, P274, DOI 10.1016/j.jalz.2016.09.008
  37. Spies PE, 2010, CNS SPECTRUMS, V15, P588, DOI 10.1017/S1092852900000560
  38. Toledo JB, 2015, BRAIN, V138, P2701, DOI 10.1093/brain/awv199
  39. Van Steenoven I, 2016, J ALZHEIMERS DIS, V54, P287, DOI 10.3233/JAD-160322
  40. Vos SJB, 2015, BRAIN, V138, P1327, DOI 10.1093/brain/awv029
  41. Wechsler DI, 1981, EXAMINERS MANUAL WEC
  42. Williams JH, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt64
  43. WILSON S, 1991, NAT HIST, P2

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/27